Vallon Pharmaceuticals Appoints Marella Thorell to Board of Directors
Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the
“Company”), a clinical-stage biopharmaceutical company primarily
focused on the development of novel drugs that are designed to
deter abuse in the treatment of CNS disorders, today announced the
appointment of Marella Thorell to its Board of Directors, effective
as of February 12, 2021 in connection with the closing of the
Company’s initial public offering.
“We are pleased to have Marella join the Board
and look forward to the valuable insight she brings. As we continue
to advance the Company, I believe Marella’s wealth of knowledge and
executive leadership experience will be a key asset in the next
phase of our growth,” commented Ofir Levi, Ph.D., Chairman of
Vallon’s Board of Directors.
“Vallon has continued to make great progress,
including its recent initial public offering of its common stock.
It is an exciting time for the Company, and I am thrilled to add my
perspective and industry experience to the Board. I look forward to
leveraging my expertise and to working alongside the management
team to unlock the full potential of Vallon’s technology,”
commented Ms. Thorell.
Ms. Thorell has established a successful track
record over the course of her more than 30-year career in finance
and operations having successfully led multiple M&A, licensing,
and fundraising transactions. She recently joined Centessa
Pharmaceuticals Limited, a next-generation biopharmaceutical
company, formed by Medicxi through the merger of 10 private biotech
companies and completion of a $250M Series A, as Head of Finance.
Prior to that, Ms. Thorell served as the Chief Financial Officer of
Palladio Biosciences, a privately owned, VC-backed, clinical-stage
biopharmaceutical company developing medicines for orphan diseases
of the kidney, leading the Company’s capital strategy and
Prior to joining Palladio Biosciences, Ms.
Thorell served as Chief Financial Officer, Chief Operating Officer
and Executive Director of Realm Therapeutics. At Realm, Ms. Thorell
was responsible for raising capital to fund the Company’s clinical
development plans and led M&A and licensing transactions. In
2019 Realm was acquired by ESSA Pharma. Ms. Thorell was appointed
to ESSA’s Board of Directors. She began her career and earned her
CPA at Ernst & Young, LLP. Subsequently, she worked for
Campbell Soup Company in finance and operational roles and served
as an executive consultant focusing on financial and human capital
needs. Ms. Thorell earned a BS in Business from Lehigh University,
magna cum laude.
About Vallon Pharmaceuticals
Vallon Pharmaceuticals Inc. is a clinical-stage
biopharmaceutical company, headquartered in Philadelphia, PA. The
Company is focused on the development of new medications to help
patients with central nervous system (CNS) disorders. The Company’s
lead investigational product candidate, ADAIR, is a novel abuse
deterrent formulation of amphetamine immediate release being
developed for the treatment of ADHD and narcolepsy. For more
information about the company, please visit www.vallon-pharma.com
or connect with us on LinkedIn or Twitter. Forward Looking
This press release contains “forward-looking
statements” that are based on the Company’s current expectations
and subject to inherent uncertainties, risks and assumptions that
are difficult to predict, including, without limitation, Vallon’s
ability to progress its business and continue its growth.
Forward-looking statements may be identified by the use of words
such as “anticipate,” “believe,” “contemplate,” “could,”
“estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “target,” “aim,” “should,”
"will,” “would,” or the negative of these words or other similar
expressions. Further, certain forward-looking statements are based
on assumptions as to future events that may not prove to be
accurate. These and other risks and uncertainties are described
more fully in the section titled “Risk Factors” in the final
prospectus related to Vallon’s initial public offering, filed with
the U.S. Securities and Exchange Commission on February 11, 2021.
Forward-looking statements contained in this announcement are made
as of this date, and the Company undertakes no duty to update such
information except as required under applicable law.
Investor Contact:JTC Team, LLCJenene